|Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych||Co-Founder, Exec. Chairman, Chief Exec. Officer and Managing Director||363.79k||N/A||62|
|Ms. Kathryn Andrews B.Com, CPA||Chief Financial Officer||102.04k||N/A||50|
|Ms. Dianne M. Angus||Chief Operating Officer||283.22k||N/A||57|
|Dr. Rudolph Emile Tanzi Ph.D.||Chief Scientific Advisor and Member of R&D Advisory Board||N/A||N/A||N/A|
|Dr. Steven D. Targum M.D.||Chief Medical Advisor||N/A||N/A||N/A|
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2 for the treatment of Alzheimers and Huntingtons diseases; and PBT434 for the treatment of Parkinsonian movement disorders. The company is also developing PBT519 for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
Prana Biotechnology Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.